# Signals Article on Putative Target Q02413 for Eosinophilic Esophagitis
Background
The protein encoded by the putative target Q02413 has emerged as a candidate of interest in the study of eosinophilic esophagitis (EoE), a chronic immune-mediated condition characterized by eosinophilic infiltration of the esophagus, leading to inflammation and esophageal dysfunction. Preliminary findings suggest that Q02413 may play a role in the inflammatory pathways and immune responses associated with EoE, indicating its potential as a therapeutic target. Given the complexity of this condition, further investigation into the molecular mechanisms involving this protein is essential for developing effective treatment strategies.Data-mining rationale
Our analysis utilized the GeoMicroarrayReanalysis approach, cross-referencing reviewed human entries in the UniProt database for "eosinophilic esophagitis" against 9 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate UniProt:Q02413 was identified as being present in several expression-profiling studies, yet it notably lacks any registered Phase 1 or higher clinical programs. This observation raises questions about its potential role in eosinophilic esophagitis and underscores the need for further exploration.Why prior analyses may have missed this
Many of the GEO datasets analyzed predate the implementation of modern empirical-Bayes statistical methods, such as the limma package, which provides robust multiple-testing correction. Consequently, previous analyses may not have accurately captured the expression dynamics of Q02413 in the context of eosinophilic esophagitis. The absence of rigorous statistical validation could explain why this candidate has not been prioritized in the search for therapeutic targets in EoE.Reasoning for further validation
To substantiate the potential role of Q02413 in eosinophilic esophagitis, several experimental approaches are warranted: 1. Re-analyze the matched GEO datasets using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to identify differentially expressed genes with greater confidence. 2. Validate the top differentially expressed genes, including Q02413, by quantitative PCR (qPCR) in an independent cohort of EoE patients to confirm expression patterns. 3. Investigate the tissue specificity of Q02413 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to determine its relevance in esophageal and immune tissues. 4. Utilize pathway analysis tools like STRING and OmniPath to contextualize Q02413 within known biological pathways related to inflammation and eosinophilic esophagitis. 5. If validation is achieved, assess the druggability of Q02413 through databases such as DGIdb and ChEMBL to explore potential therapeutic interventions.References
- [UniProt: Q02413](https://www.uniprot.org/uniprot/Q02413)
- [UniProt: P35225](https://www.uniprot.org/uniprot/P35225)
- [UniProt: Q86SJ6](https://www.uniprot.org/uniprot/Q86SJ6)
- [UniProt: P32926](https://www.uniprot.org/uniprot/P32926)
- [UniProt: Q14126](https://www.uniprot.org/uniprot/Q14126)
- [NCBI GEO Accession GDS:200228083](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200228083)
- [NCBI GEO Accession GDS:200184182](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200184182)
- [NCBI GEO Accession GDS:200075142](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200075142)
- [NCBI GEO Accession GDS:200081135](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200081135)
- [NCBI GEO Accession GDS:200054043](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200054043)